Nachum Shamir Net Worth

The estimated Net Worth of Nachum Shamir is at least $11 million dollars as of 7 September 2021. Mr. Shamir owns over 71,420 units of Luminex Corp stock worth over $7,686,226 and over the last 10 years he sold LMNX stock worth over $0. In addition, he makes $3,362,140 as President, Chief Executive Officer et Director at Luminex Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Shamir LMNX stock SEC Form 4 insiders trading

Nachum has made over 7 trades of the Luminex Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 71,420 units of LMNX stock worth $103,559 on 7 September 2021.

The largest trade he's ever made was exercising 250,000 units of Luminex Corp stock on 3 August 2020 worth over $3,982,500. On average, Nachum trades about 20,463 units every 79 days since 2014. As of 7 September 2021 he still owns at least 207,792 units of Luminex Corp stock.

You can see the complete history of Mr. Shamir stock trades at the bottom of the page.

Nachum Shamir biography

Nachum Shamir serves as President, Chief Executive Officer, Director of the Company. Mr. Shamir joined the Company on October 14, 2014 as President and Chief Executive Officer and was elected to our Board. From 2006 to 2014, Mr. Shamir was the President, Chief Executive Officer and Director of Given Imaging Ltd. (Given), a developer of the PillCam capsule and manufacturer and marketer of diagnostic products for the visualization and detection of disorders of the gastrointestinal tract, which was acquired by Covidien PLC in early 2014. Mr. Shamir currently serves on the board of directors of Strata Skin Sciences, Inc., a medical technology company which focuses on the dermatology market. Mr. Shamir holds a Bachelor of Science from the Hebrew University of Jerusalem and a Masters of Public Administration from Harvard University.

What is the salary of Nachum Shamir?

As the President, Chief Executive Officer et Director of Luminex Corp, the total compensation of Nachum Shamir at Luminex Corp is $3,362,140. There are no executives at Luminex Corp getting paid more.

How old is Nachum Shamir?

Nachum Shamir is 66, he's been the President, Chief Executive Officer et Director of Luminex Corp since 2014. There are 3 older and 10 younger executives at Luminex Corp. The oldest executive at Luminex Corp is Thomas Erickson, 69, who is the Independent Director.

What's Nachum Shamir's mailing address?

Nachum's mailing address filed with the SEC is C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM, PA, 19044.

Insiders trading at Luminex Corp

Over the last 21 years, insiders at Luminex Corp have traded over $55,627,864 worth of Luminex Corp stock and bought 685,936 units worth $10,423,148 . The most active insiders traders include G Walter Ii Loewenbaum, Douglas C Bryant et Laurence E Hirsch. On average, Luminex Corp executives and independent directors trade stock every 26 days with the average trade being worth of $888,944. The most recent stock trade was executed by Harriss T Currie on 1 March 2021, trading 5,325 units of LMNX stock currently worth $97,235.

What does Luminex Corp do?

The mission of Luminex is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. The Company offers a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. Luminex accelerates reliable answers while simplifying complexity and deliver certainty with a seamless experience.

Complete history of Mr. Shamir stock trades at Luminex Corp et STRATA Skin Sciences Inc

Luminex Corp executives and stock owners

Luminex Corp executives and other stock owners filed with the SEC include:

• Nachum Shamir,
  President, Chief Executive Officer, Director
• Harriss Currie,
  Chief Financial Officer, Senior Vice President - Finance, Treasurer
• Richard Rew,
  Senior Vice President, General Counsel and Corporate Secretary
• Todd Bennett,
  Senior Vice President - Global Sales and Customer Operations
• Randall Myers,
  Senior Vice President - Global Manufacturing and Quality
• Kenneth Samet,
  Independent Director
• Kevin McNamara,
  Independent Director
• Jimmy Kever,
  Independent Director
• Edward Ogunro,
  Lead Independent Director
• Thomas Erickson,
  Independent Director
• Stephen Eck,
  Independent Director
• Dijuana Lewis,
  Independent Director
• Eric Shapiro,
  Senior Vice President - Global Marketing
• Nancy Fairchild,
  Senior Vice President - Human Resources
• Chuck Collins,
  Senior Vice President - Research and Development
• Robert J Cresci,
  Director
• Tadd S. Lazarus,
  SVP, Chief Medical Officer
• Jay B Johnston,
  Director
• Russell S Bradley,
  VP, Strategic Planning and Bus
• G Walter Ii Loewenbaum,
  Director
• Jim D Kever,
  Director
• Gregory J Gosch,
  Vice President - Marketing
• Charles J. Collins,
  SR VP, R&D - US
• John C Carrano,
  VP, Research & Development
• J Stark Phd Thompson,
  Director
• Douglas C Bryant,
  EVP, Chief Operating Officer
• James W Jacobson,
  VP, Research & Development
• Oliver H Meek,
  VP, Manufacturing
• Randel S Martin,
  VP, Marketing/Sales
• Kristi M Richburg,
  Controller
• G Walter Ii Loewenbaum,
  Director
• C Thomas Caskey,
  Director
• Laurence E Hirsch,
  Director
• Fred C Jr Goad,
  Director
• Jeremy K Bridge Cook,
  VP, Luminex Molecular Diagn
• Michael F Pintek,
  SVP Operations
• Patrick J Balthrop,
  President, Chief Exec. Officer
• Timothy R Dehne,
  VP, Systems R&D
• David S Reiter,
  General Counsel & Secretary
• Gerard Vaillant,
  Director